Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCurtin, Francois-
dc.contributor.authorChampion, Bernard-
dc.contributor.authorDavoren, Peter-
dc.contributor.authorDuke, Sally-
dc.contributor.authorEkinci, Elif I-
dc.contributor.authorGilfillan, Chris-
dc.contributor.authorMorbey, Claire-
dc.contributor.authorNathow, Thomas-
dc.contributor.authorO'Moore-Sullivan, Trisha-
dc.contributor.authorO'Neal, David-
dc.contributor.authorRoberts, Adam-
dc.contributor.authorStranks, Stephen-
dc.contributor.authorStuckey, Bronwyn-
dc.contributor.authorVora, Parind-
dc.contributor.authorMalpass, Sam-
dc.contributor.authorLloyd, David-
dc.contributor.authorMaëstracci-Beard, Nicole-
dc.contributor.authorBuffet, Bénédicte-
dc.contributor.authorKornmann, Gabrielle-
dc.contributor.authorBernard, Corinne-
dc.contributor.authorPorchet, Hervé-
dc.contributor.authorSimpson, Richard-
dc.identifier.citationDiabetes, Obesity & Metabolism 2020; online first: 19 Februaryen_US
dc.description.abstractType 1 diabetes (T1D) is characterized by a loss of β-cell function resulting in insulin deficiency. The pathogenic human endogenous retrovirus type W envelope (pHERV-W-Env) protein is associated with T1D and may play a role in the loss of β-cells. Temelimab is a monoclonal antibody neutralizing pHERV-W-Env and we report its first study in T1D patients. This double blind placebo-controlled randomized clinical trial recruited adult T1D patients within 4 years post-diagnosis and remaining C-peptide secretion. Sixty four patients were randomized (2:1) to monthly temelimab 6 mg/kg or placebo during 24 weeks followed by a 24-week open-label extension during which all patients received temelimab. The primary objective was the safety and tolerability of temelimab. The secondary objective was to assess pharmacodynamics (PD) response such as C-peptide levels, insulin use, glycated hemoglobin (HbA1c), hypoglycemia and auto-antibodies. Temelimab was well tolerated without any group difference in the frequency or severity of adverse events. Concerning exploratory endpoints, there was no difference in the levels of C-peptide, insulin use or HbA1c between treatment groups at Weeks 24 and 48. The frequency of hypoglycemia events was reduced with temelimab (p=0.0004) at Week 24 and the level of anti-insulin antibodies was lower with temelimab (p<0.01), the other auto-antibodies did not differ between groups. Temelimab appeared safe in T1D patients. Pharmacodynamics signals (hypoglycemia and anti-insulin antibodies) under temelimab were observed. Markers of β-cell functions were not modified by treatment. These results need to be further explored in younger T1D patients with earlier disease onset. This article is protected by copyright. All rights reserved.en_US
dc.subjectPhase II studyen_US
dc.subjectdisease modifying drugen_US
dc.subjectendogenous retrovirusen_US
dc.subjectmonoclonal antibodyen_US
dc.subjecttype 1 diabetesen_US
dc.titleA Safety and Pharmacodynamics Study of Temelimab, an anti-HERV-W-Env Monoclonal Antibody, in Type 1 Diabetes Patients.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleDiabetes, Obesity & Metabolismen_US
dc.identifier.affiliationGeNeuro SA, chemin Pré-Fleuri 3, CH, Switzerlanden_US
dc.identifier.affiliationKeogh Institute for Medical Research, Nedlands, WA, Australiaen_US
dc.identifier.affiliationSouthern Star Research Pty Ltd, Australiaen_US
dc.identifier.affiliationGeNeuro SA, chemin Pré-Fleuri 3, CH, Switzerlanden_US
dc.identifier.affiliationDepartment of Pharmacology, University of Pretoria, Pretoria, South Africaen_US
dc.identifier.affiliationDivision of Clinical Pharmacology and Toxicology, Rue Perret-Gentil, University of Geneva, Geneva, Switzerlanden_US
dc.identifier.affiliationLyell McEwin Hospital, Division of Medicine, Elizabeth, Australiaen_US
dc.identifier.affiliationFaculty of Medicine and Health Sciences, Suite 407, Level 4, Department of Clinical Medicine, Macquarie University, Australiaen_US
dc.identifier.affiliationSouthern Adelaide Diabetes & Endocrine Services, Australiaen_US
dc.identifier.affiliationDepartment of Endocrinology, Barwon Health, Geelong, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, St. Vincent's Hospital, Fitzroy, Victoria, Australiaen_US
dc.identifier.affiliationMater Hospital, South Brisbane, Australiaen_US
dc.identifier.affiliationIpswich Research Institute, Ipswich, Australiaen_US
dc.identifier.affiliationAIM Centre, Australiaen_US
dc.identifier.affiliationEastern Clinical Research Unit, Eastern Health and Monash University Level 2, Box Hill, Victoria, Australiaen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationDepartment of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital, St Leonards, NSW, Australiaen_US
dc.identifier.affiliationGold Coats Hospital, Diabetes and Endocrinology, Southport, Australiaen_US
dc.type.austinJournal Article-, Elif I
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 15, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.